PR
ALNY icon

PSP Research’s Alnylam Pharmaceuticals ALNY Stock Holding History

PSP Research’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Hold
1,465
– – 0.23% 28
2026
Q1 		$485K Buy
1,465
+147
+11% +$50K 0.34% 20
2025
Q4 		$524K Buy
+1,318
New +$583K 0.46% 58

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's ALNY Position: Q2 2026 in Review

PSP Research held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,465 shares worth $441K. The position accounts for 0.23% of the portfolio, ranked #28.

PSP Research first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $524K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • PSP Research held 1,465 shares of Alnylam Pharmaceuticals worth $441K as of Q2 2026.
  • PSP Research left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.23% of PSP Research's portfolio in Q2 2026, its #28 holding.
  • PSP Research first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Alnylam Pharmaceuticals position peaked at $524K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.